Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-065239
Filing Date
2024-08-05
Accepted
2024-08-05 17:15:52
Documents
53
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0209503-10q_actinium.htm   iXBRL 10-Q 763639
2 CERTIFICATION ea020950301ex31-1_actinium.htm EX-31.1 9535
3 CERTIFICATION ea020950301ex31-2_actinium.htm EX-31.2 9659
4 CERTIFICATION ea020950301ex32-1_actinium.htm EX-32.1 3694
5 CERTIFICATION ea020950301ex32-2_actinium.htm EX-32.2 3730
6 GRAPHIC image_001.jpg GRAPHIC 37214
  Complete submission text file 0001213900-24-065239.txt   3644929

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE atnm-20240630.xsd EX-101.SCH 35941
8 XBRL CALCULATION FILE atnm-20240630_cal.xml EX-101.CAL 27509
9 XBRL DEFINITION FILE atnm-20240630_def.xml EX-101.DEF 152226
10 XBRL LABEL FILE atnm-20240630_lab.xml EX-101.LAB 316424
11 XBRL PRESENTATION FILE atnm-20240630_pre.xml EX-101.PRE 149642
56 EXTRACTED XBRL INSTANCE DOCUMENT ea0209503-10q_actinium_htm.xml XML 285405
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 241176040
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)